Resistant Hypertension Drug Jeraygo Approved in Switzerland
Swissmedic has approved Jeraygo (aprocitentan) for resistant hypertension in adults, to be used alongside at least three antihypertensives, with...
Promising New Olanzapine LAI Data Reveals No Observed PDSS
Teva spotlighted its schizophrenia portfolio at Psych Congress 2025, unveiling long-term Phase 3 data for its investigational once-monthly olanzapine...
Iovance Biotherapeutics Reports New Nasdaq Inducement Grants
Iovance Biotherapeutics has granted inducement stock options covering 22,810 shares to two new non-executive hires, with an exercise price...
Avicanna & Harrington Wellness Launch re+play CBD in US
Avicanna Latam SAS, a subsidiary of Avicanna Inc., has launched the re+play CBD wellness brand across the United States...
Breakthrough Carbon Capture Tech is Scalable and Modular
Decarbontek has launched a modular, fiber-based adsorbent platform intended to scale point-source carbon capture and direct air capture by...
Roche’s Contivue for nAMD Earns Breakthrough CE Approval
Roche has secured a European CE mark for its port delivery platform with ranibizumab, to be marketed as Contivue...
New Data on Semaglutide’s Food Noise, CV Benefits at EASD
Novo Nordisk will bring 35 presentations to EASD 2025 in Vienna, spanning late- and early-stage evidence across its semaglutide...
Idorsia’s New Initiative Offers Hope for Hypertension Care
Idorsia has launched IMPACT-HTN with the Stanford Hypertension Center and Duke Heart Center, a three-phase initiative designed to standardize...
Pioneering Quantum Partnership Aims for Biomaterials Growth
Marine Biologics has struck an exclusive partnership with Molecular Quantum Solutions that makes it the sole commercialization channel for...
New Phase 1 Study Results for NBTXR3 in Resistant Melanoma
Nanobiotix reported new Phase 1 data in primary cutaneous melanoma showing that a one-time intratumoral injection of JNJ-1900 (NBTXR3),...